PHARMACOGENETIC EVALUATION OF ANTI-HYPERTENSIVE RESPONSE (PEAR)

抗高血压反应的药物遗传学评价（梨）

• 批准号: 7603690
• 负责人: ARLENE B CHAPMAN
• 金额: $ 3.2万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7603690
• 关键词: Adrenergic beta-Antagonists; Antihypertensive Agents; Candidate Disease Gene; Computer Retrieval of Information on Scientific Projects Database; Diuretics; Evaluation; Funding; Genes; Genetic Polymorphism; Grant; Institution; Numbers; Patients; Pharmacogenetics; Purpose; Research; Research Personnel; Resources; Source; Testing; Thiazide Diuretics; United States National Institutes of Health; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the association of a large number of genes with responses to diuretics and beta-blockers in hypertensive patients. It will test the hypothesis that 1) polymorphisms in proposed candidate genes are important determinants of the inter-patient variance in antihypertensive and adverse response to B-blockers and thiazide diuretics; and 2) there are a substantial number of new genes that are important determinants of the interpatient variance in antihypertensive and adverse responses to B-blockers and thiazide diuretics.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的目的是确定大量基因与高血压患者对利尿剂和β受体阻滞剂反应的相关性。 它将检验以下假设：1）拟定候选基因的多态性是抗高血压药物和B受体阻滞剂及噻嗪类利尿剂不良反应患者间差异的重要决定因素; 2）有大量新基因是抗高血压药物和B受体阻滞剂及噻嗪类利尿剂不良反应患者间差异的重要决定因素。